Demo Environment

All companies, figures, filings and activity below are simulated sample data. Live functionality is not connected.

NASDAQ: HLIX

Helix Therapeutics Inc.

Health Care

Demo Data

Financial snapshot

Price

$91.07

Change

+2.31%

Market cap

$16.4B

Revenue (TTM)

$3.42B

Revenue growth

+11.7%

Operating margin

8.9%

EPS (TTM)

$1.36

Next event

Investor day — Sept. 22, 2026

Key changes

Chief Financial Officer	Incumbent	→ Interim, eff. Sept. 15	Form 8-K, Item 5.02
R&D expense	$241M	→ $286M	Year-over-year, Q2

Research records

HLIX · Development/JMUSY Verified

Form 8-K: CFO transition announced effective Sept. 15, 2026

The company disclosed the departure of its Chief Financial Officer and the appointment of an interim CFO effective Sept. 15, 2026. No disagreement with the company was disclosed.

JMUSY Analysis

The filing states no disagreement with the company on accounting or disclosure matters. JMUSY reports the disclosed facts only and does not infer a reason for the transition.

Jeremy Minnick

Founder & Research Analyst

Reviewed Aug. 27, 2026 · 3:05 PM ET

1 source

HLIX · Earnings/Human Verification in Progress

R&D expense up 18.4% year over year to $286M

Research and development expense of $286M versus $241M in the prior-year quarter, an 18.4% increase, driven by late-stage trial spending per management commentary.

JMUSY Analysis

Analysis is withheld until human verification is complete.

Jeremy Minnick

Founder & Research Analyst

Verification in progress

2 sources